Key facts
- An FDA advisory panel narrowly recommended easing restrictions on several peptides, including BPC-157, TB-500, and KPV.
- The panel voted 8-6 with one abstention to place these peptides on the FDA's list of substances safe for pharmacy compounding.
- FDA scientists expressed concerns that the peptides have not been proven safe or effective for medical purposes.
- The panel's recommendation is not binding, but the FDA typically follows such advice.
- Proponents argue that easier access will steer consumers away from unvetted foreign products and provide safe treatment options.
An advisory panel to the Food and Drug Administration has narrowly recommended easing restrictions on several popular peptides, despite significant concerns raised by FDA scientists regarding their safety and efficacy. The panel voted 8-6, with one abstention, in favor of allowing compounding pharmacies to produce injectable peptides such as BPC-157, TB-500, and KPV.
These peptides are widely marketed for wellness and cosmetic purposes, often promoted by celebrities and influencers. However, FDA staff scientists stated that there is insufficient data to support their safety or effectiveness for medical uses like wound healing or opioid addiction treatment. Some panel members echoed these concerns, questioning the scientific basis for the recommendations and highlighting the "Wild West" nature of the current peptide market.
Supporters of the eased restrictions, including Health Secretary Robert F. Kennedy Jr., argue that allowing U.S. pharmacies to compound these substances will provide safer access for patients and steer them away from unvetted foreign products. They believe the decision should be put back in the hands of patients, physicians, and pharmacists. The panel's votes are advisory and not binding on the FDA, though the agency often follows such recommendations.